Press release
Retinitis Pigmentosa Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight
Retinitis Pigmentosa Clinical Trials
Explore our comprehensive Retinitis Pigmentosa Pipeline Report to stay informed about the latest advancements. Download copy now @ Retinitis Pigmentosa Pipeline Outlook [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Retinitis Pigmentosa Pipeline Report
* In September 2024:- Janssen Research & Development LLC- Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene. A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
* In September 2024:- AAVantgarde Bio Srl- A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa. The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
* DelveInsight's Retinitis Pigmentosa pipeline report depicts a robust space with 45+ active players working to develop 45+ pipeline therapies for Retinitis Pigmentosa treatment.
* The leading Retinitis Pigmentosa Companies such as Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye , and others.
* Promising Retinitis Pigmentosa Therapies such as EA-2353, BS01, CPK850, hRPC, SPVN06, RST-001 , and others.
Dive into our Retinitis Pigmentosa Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Retinitis Pigmentosa Treatment Therapies [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Retinitis Pigmentosa Emerging Drugs Profile
* BIIB-112: Biogen
BIIB-112 (formerly called NSR-RPGR) consists of a standard AAV8 vector carrying a codon optimized RPGR gene. BIIB112 is in phase II clinical studies for X-linked retinitis pigmentosa treatment. In September 2018, NSR-RPGR was granted orphan drug designation for the treatment of inherited retinal dystrophies due to defects in the RPGR gene from the U.S. Food and Drug Administration.
* QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals
QR 1123 (formerly ISIS RHO 2.5Rx) is an antisense oligonucleotide, designed to specifically target the mutant P23H messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein selectively, while preserving expression of the wild type (WT) rhodopsin (RHO) protein. The therapy is currently in Phase II clinical evaluation for the treatment of Retinitis Pigmentosa. In November 2019, ProQR Therapeutics announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.
Download the Retinitis Pigmentosa Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Retinitis Pigmentosa Clinical Trials Assessment [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type
Retinitis Pigmentosa Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Dive into our detailed Retinitis Pigmentosa Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Retinitis Pigmentosa Products, Companies, and Unmet Needs [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Retinitis Pigmentosa Pipeline Report
* Coverage- Global
* Retinitis Pigmentosa Companies- Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Nacuity Pharmaceuticals, ReNeuron, ID Pharma, Allegro Ophthalmics, SparingVision, Editas Medicine, OiDE OptoEye, and others.
* Retinitis Pigmentosa Therapies- EA-2353, BS01, CPK850, hRPC, SPVN06, RST-001, and others.
* Retinitis Pigmentosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Retinitis Pigmentosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Gain valuable insights into emerging therapies and innovations with our Retinitis Pigmentosa Pipeline Report @ Retinitis Pigmentosa Market Drivers and Barriers, Future Perspectives and Analyst Views [https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
* Introduction
* Executive Summary
* Retinitis Pigmentosa: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Retinitis Pigmentosa - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Retinitis Pigmentosa Collaboration Deals
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* BIIB-112: Biogen
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* N-acetylcysteine-amide: Nacuity Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* SPVN 06: SparingVision
* Drug profiles in the detailed report.....
* Inactive Products
* Retinitis Pigmentosa Key Companies
* Retinitis Pigmentosa Key Products
* Retinitis Pigmentosa- Unmet Needs
* Retinitis Pigmentosa- Market Drivers and Barriers
* Retinitis Pigmentosa- Future Perspectives and Conclusion
* Retinitis Pigmentosa Analyst Views
* Retinitis Pigmentosa Key Companies
* Appendix
Trending Reports:
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Ashermans Syndrome Market: https://www.delveinsight.com/sample-request/ashermans-syndrome-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infection-absssi-market-insights-epidemiology-and-market-forecast
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Hepatitis D Market: https://www.delveinsight.com/report-store/hepatitis-d-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Biliary Stents Market: https://www.delveinsight.com/report-store/biliary-stents-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Chemotherapy Induced Febrile Neutropenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
• Chronic Inducible Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Chronic Refractory Gout Market: https://www.delveinsight.com/report-store/chronic-refractory-gout-market
• Clostridium Difficile Infections Cdi Market: https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-market
• Colorectal Cancer Crc Market: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market
• Contact Dermatitis Market: https://www.delveinsight.com/infographics/contact-dermatitis-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/partner-identification-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Retinitis Pigmentosa Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight here
News-ID: 3724041 • Views: …
More Releases from DelveInsight Business Research
Chronic Pulmonary Infections Treatment Market 2032: Clinical Trials, EMA, PDMA, …
(Albany, USA) DelveInsight's "Chronic Pulmonary Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Pulmonary Infections, historical and forecasted epidemiology as well as the Chronic Pulmonary Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Pulmonary Infections market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and…
Clostridium Difficile Infections Pipeline and Clinical Trials 2025: EMA, PDMA, F …
(Albany, United States) As per DelveInsight's assessment, globally, Clostridium Difficile Infections pipeline constitutes 20+ key companies continuously working towards developing 22+ Clostridium Difficile Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Clostridium Difficile Infections Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Clostridium Difficile Infections Market.
The Clostridium Difficile Infections…
Complicated Urinary Tract Infection Pipeline and Clinical Trials 2025: EMA, PDMA …
(Albany, United States) "Complicated Urinary Tract Infection (UTI) Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Complicated Urinary Tract Infection Therapeutics Market.
As per DelveInsight's assessment, globally, about 12+ key pharma and biotech companies are working on 12+ pipeline drugs in the Complicated Urinary Tract Infection therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action…
Genital Warts Clinical Trials Assessment 2025: PDMA, EMA, FDA Approvals, Medicat …
(New York, United States) "Genital Warts Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Genital Warts Market.
As per DelveInsight's assessment, globally, Genital Warts pipeline constitutes 30+ key companies continuously working towards developing 30+ Genital Warts treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Genital Warts Pipeline report embraces in-depth…
More Releases for Retinitis
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Retinitis Pigmentosa (RP) Market Focusing on intrinsic limitations 2025
Global Retinitis Pigmentosa (RP) Market: Snapshot
Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise.
Request Sample Copy of…
Retinitis Pigmentosa (Retinitis) Industry Market Expected To Grow At High Cagr D …
Overview
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/2740087-retinitis-pigmentosa-retinitis-pipeline-review-h2-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides comprehensive…
Market Research Focuses on Retinitis Pigmentosa (Retinitis) Market Pipeline Revi …
"The Report Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision…
Global Cytomegalovirus Retinitis Market Size, Share | MarketResearchReports.biz
Latest industry research report on: Global Cytomegalovirus Retinitis Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Cytomegalovirus (CMV) Retinitis is caused by cytomegalovirus infection, which is a herpes-type virus that affects the retina of the human eye among patients having a weak immune system that could be due to conditions such as AIDS, leukemia and/or pregnancy. Symptomatic conditions include floaters, flashes, and blind spots besides…
Retinitis Pigmentosa (Retinitis) Pipeline Insight and Therapeutic Assessment Rev …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Retinitis Pigmentosa (Retinitis)-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Retinitis Pigmentosa (Retinitis). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Retinitis Pigmentosa (Retinitis) by development stage, therapy…
